Phreesia, Inc. (NYSE:PHR) COO Evan Roberts Sells 2,681 Shares

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 2,681 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $27.95, for a total transaction of $74,933.95. Following the completion of the transaction, the chief operating officer now owns 769,993 shares in the company, valued at approximately $21,521,304.35. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Evan Roberts also recently made the following trade(s):

• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total transaction of $76,450.53.
• On Tuesday, October 15th, Evan Roberts sold 1,843 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total value of $38,758.29.

Phreesia Trading Down 5.9 %

Phreesia stock opened at $26.75 on Friday. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16. The stock has a market capitalization of $1.55 billion, a PE ratio of -18.20 and a beta of 0.94. The firm has a 50 day simple moving average of $22.87 and a 200-day simple moving average of $22.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period last year, the company posted ($0.58) EPS. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. As a group, equities research analysts expect that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PHR. Citigroup raised their price target on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. JMP Securities reissued a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $24.00 to $32.00 in a research report on Wednesday. KeyCorp lifted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC boosted its position in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia during the second quarter worth approximately $202,000. Point72 DIFC Ltd acquired a new position in Phreesia in the second quarter worth approximately $209,000. XTX Topco Ltd bought a new position in shares of Phreesia in the third quarter valued at $247,000. Finally, Hsbc Holdings PLC bought a new position in shares of Phreesia in the second quarter valued at $301,000. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.